secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-035229
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q2 net loss $36.9M, revenue down 28% YoY; Lilly collaboration expanded
--------------------------------------------------------------------------------

- Net loss $36.9M ($0.13/sh) vs $30.5M loss in Q2 2023; revenue $7.3M down from $10.1M.
- Partner-initiated program starts 93 cumulative (+16% YoY); molecules in clinic 14 (+56% YoY).
- Expanded Lilly collaboration to immunology, CV, neuroscience; Invetx to be acquired by Dechra for up to $520M.
- Abdera's ABD-147 received FDA IND clearance and Fast Track; AbCellera holds low-single-digit royalty and mid-single-digit equity.
- Cash and securities $697.6M plus ~$220M non-dilutive government funding; total liquidity >$900M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828024035229/0001628280-24-035229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828024035229/abcl-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer